Barely Significant
← all excerpts

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer.

Nat Med · 2022 · PMC9556333 · PMID 36097219

Europe PMCDOI
1
hedged sentence
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)
The MSS- RNF43 mutated subtype also showed a trend toward better OS compared to the MSS- RNF43 wild-type subtype (mOS of 13.6 versus 7 months; P = 0.07; HR, 0.46; 95% CI, 0.20–1.08; Fig. 3c,d and Extended Data Fig. 6c,d ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.